Scholarlink

Purpose of Review <p>This review summarizes the literature on IL-23 inhibitors for inflammatory bowel disease and the role of these agents in clinical practice.</p> Recent Findings <p>The last decade has seen several pivotal trials investigating IL-23 inhibitors. These agents are effective in inducing and maintaining remission of moderate-to-severe inflammatory bowel disease, including among those with prior biologic failure, and have low adverse events.</p> Summary <p>IL-23 inhibitors are safe and effective for treatment of moderate-to-severe inflammatory bowel disease and appear more effective than ustekinumab for Crohn’s disease. The currently available IL-23 inhibitors likely have similar efficacy, but practical considerations may influence preferences.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Interleukin-23 Inhibitors for Inflammatory Bowel Disease: Pivotal Trials and Practical Considerations

  • 期刊论文

  • 发表日期：

    2025年6月4日

查看全文
  • Sarah Rotondo-Trivette,
  • William Jennings,
  • David Fudman

摘要

Purpose of Review

This review summarizes the literature on IL-23 inhibitors for inflammatory bowel disease and the role of these agents in clinical practice.

Recent Findings

The last decade has seen several pivotal trials investigating IL-23 inhibitors. These agents are effective in inducing and maintaining remission of moderate-to-severe inflammatory bowel disease, including among those with prior biologic failure, and have low adverse events.

Summary

IL-23 inhibitors are safe and effective for treatment of moderate-to-severe inflammatory bowel disease and appear more effective than ustekinumab for Crohn’s disease. The currently available IL-23 inhibitors likely have similar efficacy, but practical considerations may influence preferences.